Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.16199
Abstract: Key Points Question Is there a difference in survival or toxic effects between the main first-line therapies used for metastatic pancreatic cancer? Findings In this comparative effectiveness study that included 1102 patients, FOLFIRINOX (combined leucovorin… read more here.
Keywords: gemcitabine plus; metastatic pancreatic; plus nab; first line ... See more keywords
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.49720
Abstract: Key Points Question Does targeting MUC5AC with the NPC-1C antibody augment the antitumor activity of gemcitabine plus nab-paclitaxel as a second-line treatment for pancreatic cancer? Findings In this randomized phase 2 trial of 78 patients… read more here.
Keywords: nab paclitaxel; advanced pancreatic; line; line gemcitabine ... See more keywords
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.1059
Abstract: Importance Adjuvant denosumab might improve disease-free survival in hormone receptor (HR)-positive primary breast cancer (BC). The optimal neoadjuvant nab-paclitaxel schedule in terms of efficacy and safety is unclear. Objective To determine whether adding denosumab to… read more here.
Keywords: denosumab; trial; nab paclitaxel; randomized clinical ... See more keywords
Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5290
Abstract: LMB‐100 is a novel immune‐conjugate (immunotoxin) that targets mesothelin. A phase 1/2 clinical trial was conducted (NCT02810418) with primary objectives assessing the safety and efficacy of LMB‐100 ± nab‐paclitaxel. Participant blood samples were analyzed for changes in… read more here.
Keywords: lmb 100; 100 nab; combination; systemic immune ... See more keywords
Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5652
Abstract: Nab‐paclitaxel (nab‐PTX) has better transfer to tumor tissue than cremophor‐based paclitaxel. It suggests that the optimum dose of nab‐PTX might be lower than the dose and schedule that is widely used. We designed a randomized… read more here.
Keywords: dose nab; previously treated; nab paclitaxel; phase trial ... See more keywords
Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5971
Abstract: BACKGROUND Neoadjuvant treatment with nab-paclitaxel and gemcitabine for potentially operable pancreatic adenocarcinoma has not been well studied in a prospective interventional trial and could down-stage tumors to achieve negative surgical margins. METHODS A single-arm, open-label… read more here.
Keywords: node positive; nab paclitaxel; borderline resectable; gemcitabine ... See more keywords
Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34589
Abstract: The objective of this study was to evaluate the safety and efficacy of nab‐paclitaxel, trastuzumab, and pertuzumab as neoadjuvant therapy (NAT) in patients with human epidermal growth factor receptor 2 HER2+ breast cancer (HER2+ BC)… read more here.
Keywords: nab paclitaxel; breast cancer; paclitaxel trastuzumab; study ... See more keywords
Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Cancer"
DOI: 10.1002/ijc.31751
Abstract: Pancreatic cancer is a highly lethal malignancy. Developments in recent years have broadened our therapeutic armamentarium. Novel drugs such as nab‐paclitaxel, liposomal irinotecan and chemotherapy regimens such as FOLFIRINOX have been successfully tested in clinical… read more here.
Keywords: nab paclitaxel; treatment; survival 174; cohort study ... See more keywords
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Final results of the NEPTUN study
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Cancer"
DOI: 10.1002/ijc.34467
Abstract: Real‐world data on the first‐line treatment of patients with advanced non‐small cell lung cancer (NSCLC) are still limited. The NEPTUN study evaluated effectiveness and safety of first‐line nab‐paclitaxel (Abraxane) plus carboplatin (nab‐P/C) in patients with… read more here.
Keywords: line nab; patients advanced; first line; nab paclitaxel ... See more keywords
Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-020-04174-1
Abstract: Purpose We conducted a phase 1 study to determine the maximum tolerated dose and the recommended dose of gemcitabine/nab-paclitaxel/S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Methods We enrolled patients aged 20 years or older… read more here.
Keywords: nab paclitaxel; unresectable pancreatic; gemcitabine; gemcitabine nab ... See more keywords
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Investigational New Drugs"
DOI: 10.1007/s10637-017-0525-1
Abstract: SummaryBackground A single center phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab (GNP) to evaluate the safety and efficacy in metastatic pancreatic adenocarcinoma (PDAC) was conducted (NCT02331251). Methods PDAC patients (pts) with measurable disease, biopsy… read more here.
Keywords: paclitaxel pembrolizumab; nab paclitaxel; study gemcitabine; gemcitabine nab ... See more keywords